rivastigmine capsule and patch	placebo	AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) score	14842	14988	Rivastigmine patch- and capsule-treated patients also showed significant improvements at week 24 on the ADCS-CGIC (p < 0.05 vs. placebo; table 2).
rivastigmine capsule and patch with concurrent Vascular risk factors (VRF)	rivastigmine capsule and patch without concurrent Vascular risk factors (VRF)	incidence of adverse events	16487	16663	there was a significant difference in the incidence of adverse events between patients with and without concurrent VRF (61.5 and 51.2%, respectively; p = 0.0004 VRF vs. no VRF;
rivastigmine capsule and patch	placebo	AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) score	1059	1169	The ADCS-CGIC significantly improved in capsule-treated patients with, and patch-treated patients without VRF.
rivastigmine capsule and patch with concurrent Vascular risk factors (VRF)	rivastigmine capsule and patch without concurrent Vascular risk factors (VRF)	incidence of adverse events	16674	17029	In each of the individual treatment groups, the overall incidence of adverse events was slightly higher in those patients who had concurrent VRF at baseline compared with those without (58.9 vs. 40.6% in the 9.5 mg/24 h patch group, 68.4 vs. 63.5% in the 17.4 mg/24 h patch group, and 68.0 vs. 58.5% in the 12 mg/day capsule group, respectively; table 3).
rivastigmine	placebo	AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale	15656	15825	Significant benefits of treatment were seen on the ADCS-ADL from baseline at week 24 in rivastigmine patch- and capsule-treated patients compared with placebo (p < 0.05;
rivastigmine	placebo	AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale	933	1058	Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF.
